Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation

Table 3 Cox regression multivariate analysis of variables for overall survival in AML patients

Variables	Whole-cohort AML		Non-M3 AML		CN-AML
Variables	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age	1.032 (1.016–1.047)	0.000	1.024 (1.008–1.041)	0.003	1.031 (1.012–1.051)	0.001
WBC	1.006 (1.001–1.010)	0.008	1.005 (1.000–1.009)	0.041	1.006 (1.001–1.011)	0.015
Molecular risks	2.112 (1.568–2.845)	0.000	2.101 (1.526–2.892)	0.000	1.769 (0.664–4.714)	0.254
Treatment regimen	0.421 (0.273–0.650)	0.000	0.389 (0.250–0.606)	0.000	0.614 (0.326–1.155)	0.131
SPAG1 expression	2.162 (1.465–3.191)	0.000	2.048 (1.377–3.047)	0.000	2.419 (1.354–4.320)	0.003

AML: acute myeloid leukemia; CN-AML: cytogenetically normal AML; WBC: white blood cell. Variables including age (continuous variables), WBC (continuous variables), treatment regimen (with transplantation vs. without transplantation) and molecular risks (good, intermediate, poor, and unknown)

ISSN: 1755-8794